Key Highlights

• Opus Genetics fell more than 9% on June 24 with no company-specific catalyst identified.

• The stock has gained approximately 282% over the prior twelve months on ophthalmic pipeline optimism.

• A pullback of approximately 9% over the prior month precedes the June 24 session's decline.

• Opus is developing phentolamine ophthalmic solution for presbyopia and APX3330 for diabetic retinopathy.

Opus Genetics (NASDAQ:IRD), a clinical-stage ophthalmology biopharmaceutical company developing phentolamine ophthalmic solution for presbyopia and APX3330 for diabetic retinopathy, fell more than 9% on June 24 in a session of general small-cap biotech weakness with no discrete clinical or regulatory catalyst identified.

The decline arrives in the context of strong longer-term performance, with Opus having gained approximately 282% over the prior twelve months on sustained investor optimism about its ophthalmic pipeline. That scale of appreciation positions the stock for profit-taking during any sector-wide risk-off session, even in the absence of adverse company-specific news.

A modest pullback of approximately 9% over the prior month preceded the June 24 session, suggesting the stock had already begun to consolidate before the broader selling pressure accelerated the correction. Phentolamine ophthalmic solution targets the presbyopia market, addressing the age-related loss of near vision that affects a substantial portion of the global population above 40 years of age. APX3330 targets a different pathway in diabetic retinopathy, adding pipeline diversification across two distinct ophthalmic indications.

The June 24 session's decline does not represent any adverse development in Opus's clinical programs.